Cassava Sciences | PTIE - Operating Profit


Cassava Sciences reported $-11.17M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Abbott USD 2.13B 281M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Cassava Sciences USD -11.17M 2.38M Mar/2026
Eisai JPY 24.73B 35.04B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Geron USD -236K 10.55M Mar/2026
J&J USD 7.48B 860M Jun/2026
Merck USD 840M 2.72B Jun/2026
Novartis USD 4.75B 515M Jun/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 667M 4.32B Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026